Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG)

Paula Cramer,Julia Von Tresckow,Jasmin Bahlo,Sandra Robrecht,Anja Engelke,Petra Langerbeins,Anna-Maria Fink,Hyatt Balke-Want,Othman Al-Sawaf,Till Seiler,Ludwig Fischer Von Weikersthal,Holger Hebart,Kirsten Fischer,Clemens-Martin Wendtner,Stephan Stilgenbauer,Barbara F Eichhorst,Michael Hallek

doi:10.1182/blood.v128.22.2044.2044

Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, Julia Von Tresckow + Show 15 more

Open Access

https://doi.org/10.1182/blood.v128.22.2044.2044

Copy DOI

Journal: Blood	Publication Date: Dec 2, 2016
Citations: 4

Affiliation: University Hospital Cologne, München Klinik Schwabing, University of Ulm, LMU Klinikum, Ludwig-Maximilians-Universität München, Klinikum St. Marien Amberg

#Research Funding #Travel Grants + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG)

Full Text